Header Logo

Jonathan Kay

Concepts (529)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Biosimilar Pharmaceuticals
26
2023
27
12.670
Why?
Arthritis, Rheumatoid
52
2024
325
11.550
Why?
Antirheumatic Agents
41
2025
214
9.090
Why?
Rheumatic Diseases
14
2023
41
4.580
Why?
Rheumatology
16
2024
65
4.560
Why?
Nephrogenic Fibrosing Dermopathy
17
2016
22
4.480
Why?
Contrast Media
16
2016
415
3.330
Why?
Gadolinium
14
2016
103
3.220
Why?
Arthritis, Psoriatic
8
2025
32
2.740
Why?
Spondylarthritis
10
2024
38
2.690
Why?
Spondylitis, Ankylosing
9
2024
24
2.650
Why?
Antibodies, Monoclonal
20
2025
860
2.500
Why?
Infliximab
12
2022
55
2.410
Why?
Methotrexate
15
2021
77
2.170
Why?
Adalimumab
9
2023
37
1.520
Why?
Humans
145
2025
61135
1.490
Why?
Kidney Failure, Chronic
12
2010
207
1.380
Why?
Drug Approval
6
2020
29
1.300
Why?
Double-Blind Method
20
2022
735
1.230
Why?
Skin Diseases
6
2016
77
1.090
Why?
United States Food and Drug Administration
3
2024
95
1.080
Why?
Joints
4
2017
32
1.070
Why?
Tumor Necrosis Factor-alpha
13
2025
588
1.060
Why?
Skin
10
2016
358
1.020
Why?
Gadolinium DTPA
4
2016
86
0.960
Why?
Treatment Outcome
28
2025
5620
0.930
Why?
Fibrosis
8
2013
154
0.890
Why?
Therapeutic Equivalency
5
2022
15
0.810
Why?
Crohn Disease
1
2023
117
0.790
Why?
Biological Therapy
4
2019
16
0.780
Why?
Middle Aged
47
2024
16831
0.780
Why?
Arthritis
2
2020
50
0.770
Why?
Male
58
2024
28692
0.760
Why?
Vasculitis
4
2024
51
0.740
Why?
Severity of Illness Index
16
2017
1511
0.730
Why?
Azetidines
1
2020
6
0.720
Why?
Female
59
2024
31658
0.710
Why?
Hematologic Agents
1
2020
3
0.700
Why?
Filgrastim
1
2020
6
0.700
Why?
Bone and Bones
3
2016
159
0.690
Why?
Adult
39
2024
16196
0.670
Why?
Scleroderma, Systemic
3
2016
21
0.650
Why?
Patient Care Management
1
2019
29
0.640
Why?
Magnetic Resonance Imaging
9
2019
2069
0.640
Why?
Practice Guidelines as Topic
6
2024
727
0.630
Why?
Kidney Diseases
3
2011
169
0.610
Why?
Anti-Inflammatory Agents, Non-Steroidal
3
2024
204
0.600
Why?
Clinical Decision-Making
1
2019
143
0.600
Why?
Spondylarthropathies
2
2019
4
0.590
Why?
Academic Medical Centers
1
2020
319
0.590
Why?
Amyloidosis
9
2008
61
0.580
Why?
United States
11
2024
7645
0.560
Why?
Organometallic Compounds
3
2016
64
0.550
Why?
Renal Insufficiency, Chronic
4
2014
118
0.550
Why?
Acquired Hyperostosis Syndrome
1
2016
1
0.550
Why?
Biological Products
3
2024
95
0.540
Why?
Osteoarthritis
3
2024
132
0.530
Why?
C-Reactive Protein
5
2019
170
0.520
Why?
United States Department of Veterans Affairs
1
2020
515
0.520
Why?
Acute-Phase Proteins
2
2014
34
0.520
Why?
Immunologic Factors
4
2015
99
0.510
Why?
Antibodies, Monoclonal, Humanized
7
2025
237
0.500
Why?
Exercise
2
2020
919
0.500
Why?
Aged
30
2019
14129
0.500
Why?
Surveys and Questionnaires
5
2022
2636
0.490
Why?
beta 2-Microglobulin
10
2001
48
0.480
Why?
Macrophages
4
2014
1011
0.470
Why?
Meglumine
2
2016
18
0.460
Why?
Peritoneum
1
2014
26
0.460
Why?
Hypophosphatemia
1
2014
6
0.460
Why?
Peritonitis
1
2014
37
0.450
Why?
Cryoglobulinemia
2
2005
3
0.450
Why?
Blood Sedimentation
1
2014
8
0.450
Why?
Immunoglobulin G
4
2018
450
0.440
Why?
Polychondritis, Relapsing
1
2013
3
0.430
Why?
Remission Induction
8
2019
143
0.430
Why?
Gastrointestinal Diseases
2
2013
77
0.420
Why?
Rare Diseases
1
2013
39
0.420
Why?
Injections, Subcutaneous
6
2021
74
0.410
Why?
Interleukin-1beta
1
2014
262
0.410
Why?
Risk Factors
11
2018
5139
0.400
Why?
Global Health
1
2013
170
0.400
Why?
Myelodysplastic Syndromes
1
2013
75
0.400
Why?
Piperazines
2
2011
83
0.380
Why?
Renal Insufficiency
2
2009
66
0.380
Why?
Drug Therapy, Combination
8
2021
463
0.380
Why?
Pyrimidines
2
2011
127
0.380
Why?
Drugs, Generic
1
2011
17
0.370
Why?
Kidney
4
2016
420
0.370
Why?
Neoplasms
3
2022
1263
0.360
Why?
Protein Kinase Inhibitors
2
2011
173
0.360
Why?
Glycation End Products, Advanced
5
2003
19
0.360
Why?
Bursitis
1
2010
13
0.360
Why?
Area Under Curve
3
2021
144
0.350
Why?
Renal Dialysis
6
2000
191
0.350
Why?
Inflammasomes
1
2014
331
0.350
Why?
Diabetes Complications
1
2010
102
0.340
Why?
Societies, Medical
5
2024
346
0.340
Why?
Autopsy
1
2009
50
0.330
Why?
Comorbidity
5
2013
1112
0.330
Why?
Sulfonamides
3
2020
410
0.330
Why?
Carrier Proteins
1
2014
704
0.330
Why?
Cost Savings
2
2020
56
0.330
Why?
Randomized Controlled Trials as Topic
4
2022
702
0.320
Why?
Software
2
2009
378
0.310
Why?
Medical Records Systems, Computerized
1
2009
66
0.310
Why?
Terminology as Topic
6
2016
139
0.310
Why?
Diagnosis, Differential
7
2016
939
0.300
Why?
Cohort Studies
5
2023
2519
0.290
Why?
Teriparatide
2
2018
6
0.290
Why?
Pulmonary Fibrosis
1
2008
77
0.290
Why?
Dose-Response Relationship, Drug
9
2019
828
0.280
Why?
Tomography, X-Ray Computed
7
2022
1538
0.280
Why?
Disease Progression
6
2017
1128
0.280
Why?
Back Pain
3
2022
51
0.270
Why?
Radiography
4
2017
518
0.270
Why?
Qualitative Research
5
2022
633
0.260
Why?
Lupus Erythematosus, Systemic
2
2024
162
0.260
Why?
Molecular Targeted Therapy
3
2017
120
0.260
Why?
Prevalence
5
2013
1314
0.260
Why?
Temporal Arteries
1
2006
4
0.260
Why?
Giant Cell Arteritis
1
2006
5
0.260
Why?
Receptors, Immunologic
5
2003
177
0.260
Why?
Clinical Trials as Topic
2
2024
453
0.260
Why?
Databases, Factual
4
2024
849
0.250
Why?
Glomerulonephritis, Membranoproliferative
1
2005
5
0.250
Why?
Cardiovascular Diseases
1
2013
844
0.250
Why?
Antibodies, Antinuclear
2
2018
38
0.250
Why?
Attitude of Health Personnel
2
2009
569
0.250
Why?
Proto-Oncogene Proteins c-bcl-2
3
2016
382
0.240
Why?
Interleukin-1
3
2004
156
0.240
Why?
Monocytes
4
2001
346
0.230
Why?
Internationality
2
2015
43
0.230
Why?
Drug Industry
3
2018
39
0.230
Why?
Healthy Volunteers
2
2021
72
0.230
Why?
Biomedical Research
2
2017
254
0.220
Why?
Antineoplastic Agents
3
2016
932
0.220
Why?
Hospitals, General
1
2023
15
0.220
Why?
Rituximab
3
2017
80
0.220
Why?
Massachusetts
3
2023
2125
0.210
Why?
Bridged Bicyclo Compounds, Heterocyclic
2
2016
305
0.210
Why?
Physicians, Primary Care
2
2021
73
0.210
Why?
Drug Costs
2
2020
59
0.210
Why?
Gout
2
2016
53
0.200
Why?
Hematologic Neoplasms
2
2016
332
0.200
Why?
Inflammation
2
2021
1109
0.200
Why?
Ultrasonography
2
2016
464
0.200
Why?
Psoriasis
1
2022
49
0.190
Why?
Europe
5
2015
187
0.190
Why?
Lymphoproliferative Disorders
1
2002
38
0.190
Why?
Dopamine
1
2022
102
0.190
Why?
Patient Care Planning
2
2019
84
0.190
Why?
Graft vs Host Disease
1
2022
105
0.190
Why?
Drug Substitution
3
2025
42
0.190
Why?
Republic of Korea
1
2021
29
0.180
Why?
Health Knowledge, Attitudes, Practice
3
2019
747
0.180
Why?
Dendritic Cells
2
2016
796
0.180
Why?
Hyperpigmentation
2
2012
6
0.180
Why?
Janus Kinase 1
1
2020
10
0.180
Why?
Janus Kinase 2
1
2020
15
0.180
Why?
Purines
1
2020
40
0.180
Why?
Animals
13
2022
20116
0.180
Why?
Aged, 80 and over
8
2016
5554
0.170
Why?
Philadelphia
1
2020
19
0.170
Why?
Depression, Postpartum
1
2023
155
0.170
Why?
Medicare Part B
1
2020
10
0.170
Why?
Fatal Outcome
3
2009
116
0.170
Why?
Legislation, Drug
1
2020
18
0.170
Why?
Synovial Fluid
2
1991
28
0.170
Why?
European Union
1
2020
11
0.170
Why?
Hepatitis C
1
2002
143
0.170
Why?
Attitude
1
2020
103
0.170
Why?
Iatrogenic Disease
1
2000
56
0.170
Why?
Reimbursement Mechanisms
1
2020
41
0.170
Why?
Personality Disorders
1
1999
19
0.170
Why?
Pyrazoles
1
2020
76
0.170
Why?
Quality of Life
5
2024
1154
0.170
Why?
Observational Studies as Topic
1
2020
61
0.170
Why?
Infusions, Intravenous
1
2020
173
0.170
Why?
Benzamides
2
2011
61
0.170
Why?
Retrospective Studies
7
2024
6186
0.170
Why?
Disability Evaluation
2
2012
217
0.170
Why?
Antibodies, Monoclonal, Murine-Derived
2
2013
57
0.170
Why?
Patient Acuity
1
2019
20
0.160
Why?
Sacroiliitis
1
2019
1
0.160
Why?
Risk Assessment
3
2019
1946
0.160
Why?
Biopsy
4
2011
409
0.160
Why?
Certolizumab Pegol
1
2019
2
0.160
Why?
Patient Participation
2
2019
218
0.160
Why?
Lyme Disease
2
1993
104
0.160
Why?
Gastroenterology
1
2020
53
0.160
Why?
Reproducibility of Results
4
2022
1598
0.160
Why?
Evidence-Based Medicine
3
2017
460
0.160
Why?
Pain
4
2024
410
0.160
Why?
Polyethylene Glycols
1
2020
166
0.160
Why?
Prospective Studies
3
2025
3182
0.160
Why?
Data Mining
1
2019
47
0.150
Why?
Cost-Benefit Analysis
1
2020
303
0.150
Why?
Consensus
2
2017
204
0.150
Why?
Glucocorticoids
2
2013
187
0.150
Why?
Guideline Adherence
3
2024
299
0.150
Why?
Anti-Citrullinated Protein Antibodies
1
2018
6
0.150
Why?
Motivation
1
2020
277
0.140
Why?
Bone Diseases, Metabolic
1
2017
21
0.140
Why?
Case-Control Studies
3
2018
1089
0.140
Why?
Health Services Needs and Demand
1
2019
215
0.140
Why?
Time Factors
9
2025
3658
0.140
Why?
Cigarette Smoking
1
2018
53
0.140
Why?
Lymphoma
1
2018
102
0.140
Why?
Bone Density Conservation Agents
1
2017
49
0.140
Why?
Review Literature as Topic
2
2016
33
0.140
Why?
Delayed Diagnosis
3
2022
43
0.140
Why?
Bipolar Disorder
1
1999
251
0.140
Why?
Snail Family Transcription Factors
1
2016
25
0.140
Why?
Social Media
1
2019
112
0.140
Why?
Biomarkers
4
2024
1347
0.140
Why?
Radionuclide Imaging
1
2016
119
0.130
Why?
Alcoholism
1
1999
312
0.130
Why?
Uric Acid
1
2016
49
0.130
Why?
Physicians
1
2021
443
0.130
Why?
Positron Emission Tomography Computed Tomography
1
2016
43
0.130
Why?
Bone Density
1
2017
172
0.130
Why?
Hand Bones
1
2016
1
0.130
Why?
Young Adult
3
2024
4414
0.130
Why?
Heterocyclic Compounds
1
2016
12
0.130
Why?
Hedgehog Proteins
1
2016
113
0.130
Why?
Drug Design
1
2017
143
0.130
Why?
Hand Joints
1
2016
21
0.130
Why?
Mass Screening
1
2021
659
0.130
Why?
International Agencies
1
2015
7
0.120
Why?
Predictive Value of Tests
2
2009
1061
0.120
Why?
Biological Availability
1
2016
201
0.120
Why?
China
2
2015
139
0.120
Why?
Drug Monitoring
1
2015
127
0.120
Why?
Bone Resorption
2
2016
49
0.120
Why?
Creatinine
3
2011
131
0.120
Why?
Advisory Committees
1
2015
109
0.110
Why?
Fibronectins
2
1991
41
0.110
Why?
CARD Signaling Adaptor Proteins
1
2014
64
0.110
Why?
Inflammation Mediators
2
2013
166
0.110
Why?
Apoptosis Regulatory Proteins
1
2014
149
0.110
Why?
Caveolin 1
1
2013
7
0.110
Why?
Ear Cartilage
1
2013
7
0.110
Why?
Self Report
1
2015
366
0.110
Why?
Scleroderma, Diffuse
1
2012
2
0.100
Why?
Transforming Growth Factor beta1
1
2013
54
0.100
Why?
Raynaud Disease
1
2012
4
0.100
Why?
Quality Assurance, Health Care
1
2015
254
0.100
Why?
Contracture
1
2012
8
0.100
Why?
Dexamethasone
1
1994
201
0.100
Why?
Imatinib Mesylate
2
2011
33
0.100
Why?
Hemoglobins
1
2013
134
0.100
Why?
Canada
1
2012
151
0.100
Why?
Hydrocortisone
1
1994
189
0.100
Why?
Osteoporosis
1
2013
137
0.100
Why?
NLR Family, Pyrin Domain-Containing 3 Protein
1
2014
256
0.100
Why?
Quality Indicators, Health Care
1
2015
330
0.100
Why?
Lung Diseases
1
2013
173
0.100
Why?
Health Services Accessibility
1
2017
551
0.100
Why?
Shoulder
2
2010
24
0.100
Why?
Arthrography
1
2011
7
0.100
Why?
North America
4
2015
120
0.100
Why?
Opsonin Proteins
1
1991
31
0.090
Why?
Dermis
1
2011
16
0.090
Why?
Health Care Surveys
2
2009
283
0.090
Why?
Shoulder Impingement Syndrome
1
2010
2
0.090
Why?
Immunosuppressive Agents
1
2013
369
0.090
Why?
Mice
5
2022
10646
0.090
Why?
Hearing Loss, Sensorineural
1
2011
46
0.090
Why?
Polymorphism, Single Nucleotide
1
2013
479
0.090
Why?
Muscular Diseases
2
2006
47
0.090
Why?
Range of Motion, Articular
1
2010
87
0.090
Why?
Adolescent
4
2016
6029
0.090
Why?
Risk Reduction Behavior
1
2011
125
0.090
Why?
International Cooperation
4
2010
83
0.090
Why?
Registries
1
2014
807
0.090
Why?
Cross-Sectional Studies
2
2015
2536
0.090
Why?
Pain Measurement
1
2011
338
0.080
Why?
Edema
2
2009
43
0.080
Why?
Recovery of Function
1
2011
271
0.080
Why?
Pilot Projects
1
2013
943
0.080
Why?
Serum Amyloid A Protein
1
2009
7
0.080
Why?
E-Selectin
1
2009
18
0.080
Why?
Drug-Related Side Effects and Adverse Reactions
1
2011
152
0.080
Why?
Thromboembolism
1
2009
71
0.080
Why?
Medical Informatics Applications
1
2009
15
0.080
Why?
Mice, Knockout
1
2014
2013
0.080
Why?
Matrix Metalloproteinase 9
1
2009
58
0.080
Why?
Interleukin-18
1
2009
74
0.080
Why?
Disease Models, Animal
2
2014
2073
0.080
Why?
Drug Eruptions
1
2008
14
0.080
Why?
Cause of Death
1
2009
208
0.080
Why?
Pregnancy
3
2023
2368
0.080
Why?
Eosinophilia
1
1988
29
0.080
Why?
Chronic Kidney Disease-Mineral and Bone Disorder
1
2008
5
0.080
Why?
Chondrocalcinosis
1
2008
3
0.080
Why?
Receptors, Cell Surface
1
1991
436
0.080
Why?
Uremia
1
2008
9
0.080
Why?
Health Status
1
2011
448
0.080
Why?
Patient Satisfaction
1
2011
421
0.070
Why?
Peripheral Nervous System Diseases
1
2008
27
0.070
Why?
Joint Diseases
1
2008
18
0.070
Why?
Receptor for Advanced Glycation End Products
3
2003
19
0.070
Why?
Proportional Hazards Models
1
2009
691
0.070
Why?
Drug Resistance
1
2008
95
0.070
Why?
Insulin Resistance
1
2011
409
0.070
Why?
Syndrome
1
2007
175
0.070
Why?
Acanthamoeba
1
2006
1
0.070
Why?
Amebiasis
1
2006
1
0.070
Why?
Mice, Inbred C57BL
1
2014
3236
0.070
Why?
Shock, Septic
1
2008
90
0.070
Why?
Granuloma
1
2006
41
0.070
Why?
Pneumonia
1
2009
281
0.070
Why?
Granulomatosis with Polyangiitis
1
2006
14
0.070
Why?
Encephalitis
1
2006
33
0.070
Why?
Acute-Phase Reaction
3
2010
18
0.070
Why?
Diabetes Mellitus, Type 2
2
2011
679
0.070
Why?
Synovitis
3
2010
31
0.060
Why?
Pharyngitis
1
2006
12
0.060
Why?
Myocardium
1
2008
265
0.060
Why?
Mental Disorders
1
2013
791
0.060
Why?
Early Diagnosis
3
2010
95
0.060
Why?
Rocky Mountain Spotted Fever
1
2005
1
0.060
Why?
Knee Joint
1
2008
287
0.060
Why?
Autoantibodies
2
2018
176
0.060
Why?
Follow-Up Studies
2
2009
2404
0.060
Why?
Exanthema
1
2005
27
0.060
Why?
Prednisone
1
2005
86
0.060
Why?
Pragmatic Clinical Trials as Topic
1
2025
6
0.060
Why?
Logistic Models
2
2019
1268
0.060
Why?
Fatigue
1
2006
106
0.060
Why?
Dyspnea
1
2006
121
0.060
Why?
Clinical Trials, Phase III as Topic
1
2025
38
0.060
Why?
Xenograft Model Antitumor Assays
2
2016
470
0.060
Why?
Multicenter Studies as Topic
1
2025
131
0.060
Why?
Precision Medicine
2
2016
393
0.060
Why?
Survival Analysis
2
2016
847
0.060
Why?
Receptors, Interleukin-1
1
2004
65
0.060
Why?
Interleukin-23
1
2024
18
0.060
Why?
Cell Survival
2
2016
849
0.060
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2006
215
0.060
Why?
Anorexia Nervosa
1
1983
16
0.050
Why?
Rabbits
1
2004
329
0.050
Why?
Time-to-Treatment
1
2024
100
0.050
Why?
Research Design
2
2017
579
0.050
Why?
Models, Animal
1
2004
223
0.050
Why?
Collagen
3
1998
117
0.050
Why?
Epidemiologic Methods
2
2014
68
0.050
Why?
Chromosomes, Human, Pair 3
1
2002
12
0.050
Why?
Glucans
2
1994
63
0.050
Why?
Ion Channels
1
2022
89
0.050
Why?
Trisomy
1
2002
19
0.050
Why?
Cell Line, Tumor
2
2016
1675
0.050
Why?
Cell Proliferation
2
2016
1238
0.050
Why?
Etanercept
2
2013
32
0.050
Why?
Receptors, Tumor Necrosis Factor
2
2013
62
0.050
Why?
Sports Medicine
1
2021
22
0.050
Why?
Cytokines
2
2016
910
0.050
Why?
Syringes
1
2021
11
0.050
Why?
General Practitioners
1
2021
15
0.050
Why?
Phagocytosis
2
1994
252
0.050
Why?
Sex Factors
1
2024
984
0.050
Why?
Longitudinal Studies
1
2025
1267
0.050
Why?
Cost of Illness
1
2022
155
0.040
Why?
Triazoles
1
2021
52
0.040
Why?
Chronic Disease
2
2016
753
0.040
Why?
Psychometrics
1
2022
365
0.040
Why?
Pyridines
1
2021
97
0.040
Why?
Hypertension
1
2005
615
0.040
Why?
Congresses as Topic
1
2019
73
0.040
Why?
Psychiatric Status Rating Scales
1
1999
396
0.040
Why?
Brain
1
2006
1513
0.040
Why?
Guanidines
1
1998
14
0.040
Why?
Denmark
1
2018
22
0.040
Why?
Sweden
1
2018
43
0.040
Why?
Lymphoma, Follicular
1
2018
15
0.040
Why?
Electronic Health Records
1
2021
356
0.040
Why?
Cognition
1
2022
480
0.040
Why?
Immunoglobulin M
1
2018
113
0.040
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2018
39
0.040
Why?
Ulna
1
2017
4
0.040
Why?
Radius
1
2017
13
0.040
Why?
Lymphoma, Non-Hodgkin
1
2018
51
0.040
Why?
Metacarpophalangeal Joint
1
2017
9
0.040
Why?
Infant
1
2022
1542
0.040
Why?
Hodgkin Disease
1
2018
56
0.040
Why?
Lymphoma, Large B-Cell, Diffuse
1
2018
66
0.040
Why?
Immunoglobulin A
1
2018
95
0.030
Why?
Cicatrix, Hypertrophic
1
2016
1
0.030
Why?
Patched Receptors
1
2016
11
0.030
Why?
Keloid
1
2016
3
0.030
Why?
Medication Therapy Management
1
2017
26
0.030
Why?
Aging
1
2003
740
0.030
Why?
Glycogen Synthase Kinase 3 beta
1
2016
26
0.030
Why?
Membrane Proteins
1
2022
852
0.030
Why?
Health Priorities
1
2016
23
0.030
Why?
Carpal Tunnel Syndrome
1
1996
28
0.030
Why?
beta Catenin
1
2016
86
0.030
Why?
Cicatrix
1
2016
58
0.030
Why?
Evaluation Studies as Topic
1
1996
108
0.030
Why?
Fibroblasts
1
1998
379
0.030
Why?
Pharmacovigilance
1
2016
15
0.030
Why?
Cells, Cultured
3
2001
2107
0.030
Why?
Medicaid
1
2019
352
0.030
Why?
Intention to Treat Analysis
1
2015
19
0.030
Why?
Enzyme Inhibitors
1
1998
351
0.030
Why?
Odds Ratio
1
2018
776
0.030
Why?
ROC Curve
1
1996
275
0.030
Why?
Apoptosis
1
2001
1045
0.030
Why?
Guidelines as Topic
1
2016
159
0.030
Why?
Osteogenesis
1
2016
150
0.030
Why?
Primary Health Care
1
2021
665
0.030
Why?
Asia
1
2015
18
0.030
Why?
Medicare
1
2019
603
0.030
Why?
Needs Assessment
1
2016
191
0.030
Why?
Treatment Failure
1
2015
192
0.030
Why?
Algorithms
2
2010
1019
0.030
Why?
Immunohistochemistry
2
1998
858
0.030
Why?
Anti-Bacterial Agents
2
1993
745
0.030
Why?
Life Style
1
2016
334
0.030
Why?
Electrophoresis, Gel, Two-Dimensional
2
1991
39
0.030
Why?
Activities of Daily Living
1
1996
305
0.030
Why?
Medication Adherence
1
2016
246
0.030
Why?
Receptors, Interleukin-6
1
2014
16
0.030
Why?
Blood Proteins
1
1994
76
0.030
Why?
Analysis of Variance
2
2009
597
0.030
Why?
Sensitivity and Specificity
1
1996
1123
0.030
Why?
Codon
1
2013
49
0.030
Why?
Gene Frequency
1
2013
132
0.030
Why?
Feasibility Studies
1
2015
532
0.030
Why?
Patient Education as Topic
1
2016
455
0.030
Why?
Drug Administration Schedule
1
2013
292
0.030
Why?
Introns
1
2013
104
0.030
Why?
Shoulder Joint
1
1992
23
0.020
Why?
Chi-Square Distribution
1
2013
411
0.020
Why?
Acute Kidney Injury
1
2014
133
0.020
Why?
Bone Diseases
1
1992
22
0.020
Why?
Image Processing, Computer-Assisted
1
2016
650
0.020
Why?
Bacterial Vaccines
1
1993
87
0.020
Why?
Anemia
1
2013
120
0.020
Why?
Kinetics
1
1994
755
0.020
Why?
Cell Line
2
1998
2012
0.020
Why?
Precipitin Tests
1
1991
79
0.020
Why?
Chromatography, Affinity
1
1991
48
0.020
Why?
Molecular Weight
1
1991
187
0.020
Why?
Cell Count
1
2011
130
0.020
Why?
Clinical Chemistry Tests
1
2010
6
0.020
Why?
Decision Making, Computer-Assisted
1
2010
12
0.020
Why?
Multivariate Analysis
1
2013
925
0.020
Why?
Osteoclasts
1
2010
51
0.020
Why?
Epitopes
1
1991
294
0.020
Why?
Receptors, Cytoadhesin
1
1989
1
0.020
Why?
Receptors, Very Late Antigen
1
1989
1
0.020
Why?
Blotting, Western
1
1991
596
0.020
Why?
Antigens, Differentiation, T-Lymphocyte
1
1989
106
0.020
Why?
Tissue Inhibitor of Metalloproteinase-1
1
2009
8
0.020
Why?
Leg
1
2009
85
0.020
Why?
Genetic Predisposition to Disease
1
2013
698
0.020
Why?
Phenotype
1
2013
1154
0.020
Why?
Drug Synergism
1
2009
133
0.020
Why?
Osteoblasts
1
2010
207
0.020
Why?
Antibodies
2
2001
180
0.020
Why?
Safety
1
2009
145
0.020
Why?
Borrelia
1
1988
24
0.020
Why?
Calcium Oxalate
1
2008
12
0.020
Why?
Decision Support Techniques
1
2010
181
0.020
Why?
Bone Remodeling
1
2008
25
0.020
Why?
Fluorescent Antibody Technique
1
1988
219
0.020
Why?
Crystallization
1
2008
97
0.020
Why?
Patient Selection
1
2010
465
0.020
Why?
Receptors, Antigen, T-Cell
1
1989
282
0.020
Why?
Antibodies, Bacterial
1
1988
184
0.020
Why?
Incidence
1
2011
1276
0.020
Why?
Glycosylation
2
1998
133
0.020
Why?
Blood Chemical Analysis
1
2006
22
0.020
Why?
Arm
1
2006
42
0.020
Why?
Lymphocyte Activation
1
1989
745
0.020
Why?
Muscle Weakness
1
2006
29
0.020
Why?
Controlled Clinical Trials as Topic
1
2006
6
0.020
Why?
Seizures
1
2006
119
0.020
Why?
CD4-Positive T-Lymphocytes
1
1989
623
0.020
Why?
Eosinophilia-Myalgia Syndrome
1
2004
1
0.010
Why?
Acanthocytes
1
1983
1
0.010
Why?
Bone Marrow Examination
1
1983
8
0.010
Why?
Leukopenia
1
1983
17
0.010
Why?
In Vitro Techniques
2
1998
472
0.010
Why?
Leukocyte Count
1
1983
97
0.010
Why?
Dietary Proteins
1
1983
55
0.010
Why?
Dietary Carbohydrates
1
1983
78
0.010
Why?
Child
1
1993
4377
0.010
Why?
Disease Susceptibility
1
1983
159
0.010
Why?
Complement System Proteins
1
1983
115
0.010
Why?
Staphylococcal Infections
1
1983
118
0.010
Why?
Attitude to Health
1
1983
288
0.010
Why?
Superoxides
1
2001
69
0.010
Why?
Fas Ligand Protein
1
2001
39
0.010
Why?
Intracellular Membranes
1
2001
49
0.010
Why?
Dinoprostone
1
2001
44
0.010
Why?
fas Receptor
1
2001
54
0.010
Why?
Antigens, Surface
1
2001
193
0.010
Why?
Lysosomes
1
2001
158
0.010
Why?
Propionibacterium acnes
1
1979
6
0.010
Why?
Stress, Psychological
1
1983
457
0.010
Why?
Procollagen
1
1998
10
0.010
Why?
Cytotoxicity, Immunologic
1
1979
145
0.010
Why?
Gastric Mucosa
1
1998
53
0.010
Why?
Epidermal Growth Factor
1
1998
48
0.010
Why?
Spectrometry, Fluorescence
1
1998
91
0.010
Why?
Immunoblotting
1
1998
188
0.010
Why?
Membrane Glycoproteins
1
2001
669
0.010
Why?
Enzyme-Linked Immunosorbent Assay
1
1998
459
0.010
Why?
Intestinal Mucosa
1
1998
229
0.010
Why?
Glucose
1
1998
448
0.010
Why?
T-Lymphocytes
1
1979
978
0.010
Why?
RNA, Messenger
1
1998
1466
0.010
Why?
Hip
1
1992
9
0.010
Why?
Wrist
1
1992
32
0.010
Why?
Spine
1
1992
48
0.010
Why?
Integrin beta1
1
1989
27
0.010
Why?
CD3 Complex
1
1989
64
0.010
Why?
Antigens, Differentiation
1
1989
138
0.010
Why?
Extracellular Matrix
1
1989
132
0.000
Why?
Ascitic Fluid
1
1979
12
0.000
Why?
Leukemia, Experimental
1
1979
19
0.000
Why?
Mice, Inbred CBA
1
1979
83
0.000
Why?
Cell Separation
1
1979
147
0.000
Why?
Cell Adhesion
1
1979
207
0.000
Why?
Immunity, Cellular
1
1979
176
0.000
Why?
Spleen
1
1979
486
0.000
Why?
Kay's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (529)
Explore
_
Co-Authors (13)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_